Skip to contentK
Kraig Biocraft Laboratories, Inc.
K
KBLBKraig Biocraft Laboratories, Inc. Q2 2021 · 10-Q
Revenue$0.00$0.00— vs Q2 2020 Net Income-$2.75M-$2.75MN/M vs Q2 2020 EPS Diluted$0.00$0.00— vs Q2 2020 Operating Income-$705,180N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kraig Biocraft Laboratories, Inc. · CIK 1413119 · Engraved from SEC EDGAR
derived
ended Jun 30, 2021 · filed Aug 12, 2021 · 43 d after period end